|
Administration
May be taken with or without food.
|
|
Contraindications
Hypersensitivity. Pregnancy. Concomitant use with metronidazole.
|
|
Special Precautions
Patient with Crohn's ileitis or ulcerative colitis. Hepatic impairment. Children. Lactation. Monitoring Parameters Monitor CBC when used at higher doses and for a prolonged duration. Check for helminth ova in faeces within 3-4 weeks after the initial therapy.
|
|
Adverse Reactions
Significant: Reversible liver function disturbances, hepatitis, neutropenia, agranulocytosis.
Gastrointestinal disorders: Abdominal pain, diarrhoea, flatulence, nausea, vomiting.
Metabolism and nutrition disorders: Anorexia.
Nervous system disorders: Dizziness, convulsions.
Renal and urinary disorders: Glomerulonephritis.
Skin and subcutaneous tissue disorders: Alopecia, angioedema, rash, urticaria.
Potentially Fatal: Rarely, toxic epidermal necrolysis, Stevens-Johnson syndrome. |
|
Drug Interactions
Cimetidine may increase the plasma concentration of mebendazole.
|
|
CIMS Class
|
|
ATC Classification
P02CA01 - mebendazole ; Belongs to the class of benzimidazole derivative agents. Used as antinematodal.
|
Sign Out
